drugset / Trial / NCT00505258

Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia

NCT00505258 ↗

Phase 2 Withdrawn Basilea Pharmaceutica
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of ceftobiprole versus a comparator in hospitalized patients with bacteremia.

Timeline

Start
—
Primary completion
—
Completion
2009-04

Outcome

Outcome not reported

Stopped: “The study was withdrawn due to lack of an appropriate patient population.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftobiprole Small molecule 500 mg —